Research Links HOXD13 Protein to Melanoma Growth and Immune Evasion
Similar Articles
Cancer Vulnerability Discovered in Vitamin B7-Dependent Enzyme
Pre-Surgery Immunotherapy Shows Promise for a Subtype of Colorectal Cancer
Immunotherapy Shows Promise as Pre-Surgery Treatment for Specific Bowel Cancer
Research Identifies Protein Target That Improves Memory in Alzheimer's Mouse Model
New Imaging Technique Reveals Immune Cell Killing Machinery
Scientists have identified a key protein, HOXD13, that helps melanoma tumors grow and hide from the immune system. Reducing HOXD13 activity in experiments led to smaller tumors and allowed more immune cells to attack the cancer. This discovery points to potential new targets for treatment, with related drugs already in clinical trials.
Facts First
- HOXD13 transcription factor drives melanoma growth by activating pathways that increase blood flow to tumors.
- High HOXD13 levels correlate with fewer cancer-fighting T cells in patient blood and tumors.
- Blocking HOXD13 activity in experiments resulted in smaller tumors and increased T cell infiltration.
- The protein works by increasing CD73 and adenosine, which create a barrier that slows T cells.
- Clinical trials are testing drugs that block related pathways (VEGF and adenosine receptors) in melanoma.
What Happened
Researchers from NYU Langone Health identified that the transcription factor HOXD13 is linked to melanoma growth and the evasion of immune defenses. The study, published in the journal Cancer Discovery, analyzed tumor samples from more than 200 melanoma patients in the United States, Brazil, and Mexico. Experiments confirmed that HOXD13 drives blood vessel growth and immune system evasion. Melanoma patients with high levels of HOXD13 exhibited fewer cytotoxic T cells in their blood, and in these patients, T cells were less able to enter tumors.
Why this Matters to You
This research may lead to more effective treatments for melanoma, a serious form of skin cancer. If you or someone you know faces a melanoma diagnosis, understanding how tumors evade the immune system is a critical step toward developing therapies that could help your body's own defenses fight the cancer. The study's findings suggest that targeting the HOXD13 pathway could potentially make existing immunotherapies work better for more patients.
What's Next
Clinical trials are currently testing drugs that block VEGF receptors or adenosine receptors in melanoma and other cancers, some of which combine these drugs with immunotherapy. The new research on HOXD13 provides a clearer biological rationale for these approaches and could help identify which patients are most likely to benefit. Further research is likely needed to develop direct inhibitors of HOXD13 itself.